Juehua Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Juehua Gao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Changchuin Mao
Antagen Pharmaceuticals, Inc. , Canton, MA 02021
1 shared publication - Esther Landesman-Bollag
Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
1 shared publication - Gustavo Mostoslavsky
Affiliations Center for Regenerative Medicine (CReM), Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States of America, Department of Medicine, Section of Gastroenterology; Department of Virology, Immunology, and Microbiology. Boston University Chobanian & Avedisian School of Medicine, Boston Massachusetts, United States of America
1 shared publication - Haohai Zhang
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
1 shared publication - Justin Mark Lunderberg
Department of Anesthesiology Center for Inflammation Research Beth Israel Deaconess Medical Center Harvard Medical School Boston MA United States
1 shared publication - Lili Feng
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
1 shared publication
Latest Publications
- Open Access
- 15 January 2022
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 5 (1) , 55-62
Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test
Although mRNA vaccines against SARS-CoV-2 were highly efficacious against severe illness and hospitalization, they seem to be less effective in preventing infection months after vaccination, especially with the Delta variant. Breakthrough infections might be due to higher infectivity of the variants, relaxed protective measures by the general public in “COVID-19 fatigue”, and/or waning immunity post-vaccination. Determining the neutralizing antibody levels in a longitudinal manner may address this issue, but technical complexity of classic assays precludes easy detection and quick answers. We developed a lateral flow immunoassay NeutraXpress™ (commercial name of the test kit by Antagen Diagnostics, Inc.) and tested fingertip blood samples of subjects receiving either Moderna or Pfizer vaccines at various time points. With this device, we confirmed the reported clinical findings that mRNA vaccine-induced neutralizing antibodies quickly wane after 3–6 months. Thus, using rapid tests to monitor neutralizing antibody status could help identify individuals at risk, prevent breakthrough infections, and guide social behavior to curtail the spread of COVID-19.
- 15 January 2022
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 5 (1) , 55-62
Open AccessLongitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test
Although mRNA vaccines against SARS-CoV-2 were highly efficacious against severe illness and hospitalization, they seem to be less effective in preventing infection months after vaccination, especially with the Delta variant. Breakthrough infections might be due to higher infectivity of the variants, relaxed protective measures by the general public in “COVID-19 fatigue”, and/or waning immunity post-vaccination. Determining the neutralizing antibody levels in a longitudinal manner may address this issue, but technical complexity of classic assays precludes easy detection and quick answers. We developed a lateral flow immunoassay NeutraXpress™ (commercial name of the test kit by Antagen Diagnostics, Inc.) and tested fingertip blood samples of subjects receiving either Moderna or Pfizer vaccines at various time points. With this device, we confirmed the reported clinical findings that mRNA vaccine-induced neutralizing antibodies quickly wane after 3–6 months. Thus, using rapid tests to monitor neutralizing antibody status could help identify individuals at risk, prevent breakthrough infections, and guide social behavior to curtail the spread of COVID-19.